Summit Therapeutics SMMT PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's PP&E (net)?
- Summit Therapeutics (SMMT) reported PP&E (net) of $1.66M in Q1 2026.
- How has Summit Therapeutics's PP&E (net) changed year-over-year?
- Summit Therapeutics's PP&E (net) increased by 155.2% year-over-year, from $652K to $1.66M.
- What is the long-term trend for Summit Therapeutics's PP&E (net)?
- Over 5 years (2020 to 2025), Summit Therapeutics's PP&E (net) has grown at a 7.9% compound annual growth rate (CAGR), from $725K to $1.06M.
- What does PP&E (net) mean?
- The value of physical assets like equipment and facilities after accounting for wear and tear.
- How do you interpret PP&E (net)?
- An increase suggests capital investment in infrastructure, while a decrease reflects depreciation or asset disposal.
- How does PP&E (net) compare across companies?
- Biotech firms often have lower PPE relative to manufacturing companies, focusing instead on R&D spend.